The upcoming November 2020 presidential and congressional elections represent a key event for the pharma industry. Current industry focus is on COVID-19, the effects from public policy mandates on pharma business operations, resulting in recessionary effects on market access and affordability, and the search for effective vaccines and treatments. Yet, a Democratic Party election sweep by winning the White House and controlling both the Senate and House will have expected significant consequences for the pharma industry. This white paper lays out what policies could be enacted under this scenario and what pharma companies need to do to plan for this real possibility.
Contact us at firstname.lastname@example.org with any questions.